written on 24.03.2014
Tags:
,

Celgene thinks its Otezla pill will be easy for the market to swallow

TAGS: ,

With its FDA approval for psoriatic arthritis, Celgene's Otezla (apremilast) comes into a market dominated by some of the best-selling drugs in the world, including AbbVie's top seller Humira and Enbrel from Amgen and Pfizer. But instead of an injection, Celgene's drug is a pill, an advantage the company thinks will help it eventually reach up to $2 billion in sales–a figure analysts feel less certain about.

Latest Report